Madic Medical Secures Tens of Millions in Series A Funding to Advance Automation in Clinical Diagnostics

VCBeat (WeChat: vcbeat) learned at the earliest opportunity that, recently, a company focused on the research and development of automated medical laboratory productsofChangsha Medike Intelligent Technology Co., Ltd.（The following abbreviationsName“Medic”) completed a Series A financing round of tens of millions of RMB, with the investment coming from the Leading Health Care Fund under Yushan Capital (LowerTitle“Leading Health”).The funds raised in this round of financing will be used to further expand production capacity and accelerate product research and development upgrades.

Founded in 2016, Medico has been dedicated to the development of automated products in the fields of blood systems and in vitro diagnostics (IVD). It is one of the few domestic suppliers with comprehensive independent intellectual property rights for automated liquid handling platforms and automated laboratory automation lines. The company aims to leverage its technological expertise to break the long-standing monopoly of imported brands on automated equipment in China’s IVD and blood management sectors. Founder Wang Peng has focused on the blood and laboratory diagnostics fields for 23 years. The company’s independently developed products, all of which are currently commercially available, include automated nucleic acid testing (NAT) assembly lines, automated nucleic acid extraction workstations, tube aliquoting and processing systems, automated sample processing systems, intelligent blood supply platforms, and smart cold chain monitoring systems.

Medic is one of the very few domestic enterprises capable of independently developing and manufacturing high-precision pipetting pumps. Its high-precision pipetting pumps and control systems, endowed with fully independent intellectual property rights, deliver sample addition accuracy comparable to that of global industry leaders. The automated liquid handling system enables highly challenging non-uniform spacing dispensing, offering customers a degree of flexibility unattainable by conventional uniform-spacing products. Real-time monitoring is implemented during tip picking and ejection steps, while dual-channel liquid level detection—combining capacitive and pressure sensing—effectively prevents missed detections and failed pickups, ensuring precise micro-volume pipetting. Adhering to its core philosophy of an open work platform, Medic efficiently develops product series tailored to diverse application scenarios. Current derivatives of its automated liquid handling platforms include various models of fully automated nucleic acid extraction workstations, aliquoting processing systems, and blood typing analyzers. Since their market launch, these products have garnered significant attention, established strategic collaborations with multiple leading domestic nucleic acid diagnostics companies, achieved widespread installation both domestically and internationally, and earned outstanding user acclaim.

Medic’s Intelligent Blood Supply Platform pioneers the “random bag access” technology, revolutionizing conventional storage practices in the industry. It effectively circumvents the issue of repeated removal and return of blood products inherent in current blood bank refrigerators or full-rack automated storage systems, thereby preventing significant temperature fluctuations that could compromise blood quality. Furthermore, this product addresses critical pain points in blood banks, such as easy frost formation, difficult physical inventory checks, challenging traceability, and difficulties in achieving intelligent management, while effectively balancing precise retrieval with operational efficiency. The system has been installed in multiple blood stations across China. In conjunction with Medic’s Fully Automated Sample Processing System and Intelligent Cold Chain Monitoring System, it has helped establish the first batch of demonstrative models for intelligent blood stations in China.

Intelligent Red Blood Cell Refrigerator

Intelligent Plasma Freezer

Regarding this round of financing,Mr. Wang PengHe stated, “First and foremost, I would like to express our gratitude to our team for their perseverance through the challenges of independent R&D, consistently launching automation and intelligent products that effectively address our customers’ pain points. We also extend our thanks to Lingxian Health for providing financial support during our capacity expansion phase, enabling the company to enter a high-growth trajectory earlier than anticipated. Furthermore, we appreciate the trust of our partners in sharing opportunities for overseas expansion, allowing our products to reach international markets. We firmly believe that intelligent solutions, grounded in a deep understanding of application scenarios and supported by advanced technologies, will emerge and increasingly shine in the in vitro diagnostics (IVD) and blood industries. Our company aims to build a platform-oriented enterprise centered on solutions and backed by advanced technologies, delivering comprehensive and efficient intelligent construction solutions within the industry. By adopting the strategy of ‘commercializing one generation, storing one generation, and developing one generation,’ we ensure that our products maintain technological leadership and strong scenario alignment, keeping us at the forefront of the industry.”

Mr. Wu Jialu, Founder of Linghang Health FundIt stated: “China’s in vitro diagnostics (IVD) market is vast in scale and leads the world in growth rate. In recent years, the proportion of domestic substitution for diagnostic reagents and consumables has continued to rise; however, the high-end diagnostic equipment market—characterized by high throughput, automation, and even intelligence—remains dominated by imported brands. Following a rapid elevation in the technological level of domestic reagents and consumables, the focus of competition has gradually shifted from mere reagent R&D toward providing efficient solutions. In this new round of competition, high-end diagnostic equipment, as the core component of these solutions, is moving from the background to the forefront. This shift will bring significant industry opportunities and is highly likely to usher in a golden age for Chinese manufacturers of high-end diagnostic equipment. We believe that Medick, as a medical automation product R&D enterprise with profound technical accumulation and forward-looking industry insight, is well-positioned to lead in this new round of industry upgrading. Medick’s R&D system, centered on an open automated work platform, will also endow it with exceptional customized R&D capabilities. We are honored to partner with such a high-caliber team and witness the outstanding achievements of leading Chinese domestic brands in the high-end segments of IVD and hematology.”

Linghang Health is a venture capital fund founded by seasoned medical investment professionals, dedicated to early-stage investments in the healthcare and medical industry. Adhering to the philosophy of “Focus and Professionalism,” we deeply explore development trends and investment opportunities within the healthcare sector, filtering out noise and distractions to pursue genuine investment returns.